Ardelyx (NASDAQ: ARDX)
FY 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-12-20 | ||||||
REV |
FY 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-11-09 | ||||||
REV |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Ardelyx (NASDAQ: ARDX) through any online brokerage.
Other companies in Ardelyx’s space includes: Fortress Biotech (NASDAQ:FBIO), Adverum Biotechnologies (NASDAQ:ADVM), OncoCyte (NASDAQ:OCX), Inozyme Pharma (NASDAQ:INZY) and TCR2 Therapeutics (NASDAQ:TCRR).
The latest price target for Ardelyx (NASDAQ: ARDX) was reported by Cantor Fitzgerald on Friday, August 12, 2022. The analyst firm set a price target for 4.00 expecting ARDX to rise to within 12 months (a possible 330.57% upside). 50 analyst firms have reported ratings in the last year.
The stock price for Ardelyx (NASDAQ: ARDX) is $0.929 last updated August 12, 2022, 8:00 PM UTC.
The next Ardelyx (ARDX) dividend date is projected to be Thursday, September 1, 2022.
Ardelyx’s FY earnings are confirmed for Wednesday, December 20, 2023.
There is no upcoming split for Ardelyx.
Ardelyx is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.